Imaging Approaches in Prostate Cancer
Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, describes imaging approaches in prostate cancer.
Clinical Pearls I
Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, describes imaging approaches in prostate cancer.
- Sodium fluoride PET represents a sensitive way of detecting bone metastases
- Sodium fluoride PET is reasonable to use before treatment with enzalutamide, sipuleucel-T, or abiraterone, in patients with rising PSA and negative conventional imaging
Clinical Pearls II
- The Artemis device is being looked at in clinical studies to help detect prostate cancer in localized biopsies
- Sodium acetate PET and amino acid imaging are still under investigation
- Petrylak is interested in research into imaging for targeted therapies to check for activity and eligibility
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
